SINE-AID IB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SINE-AID IB (SINE-AID IB).
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
| Metabolism | Hepatic metabolism via CYP2C9 and glucuronidation. Minor pathways include CYP2C19 and CYP3A4. |
| Excretion | Renal excretion of unchanged drug and metabolites: ~90% renal, ~10% biliary/fecal. |
| Half-life | Terminal elimination half-life: 2-4 hours (mean ~2.5 h). In elderly or hepatic impairment, may be prolonged up to 6-8 hours. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd ~0.1-0.2 L/kg, indicating limited extravascular distribution; primarily confined to plasma and interstitial fluid. |
| Bioavailability | Oral: 85-95% (subject to first-pass metabolism); rectal suppository: ~70-80%; topical: minimal systemic absorption (<5%). |
| Onset of Action | Oral: 30-60 minutes; onset of analgesic effect typically within 1 hour. |
| Duration of Action | 4-6 hours for analgesia; antipyretic effect lasts 6-8 hours. Duration may be shorter with immediate-release formulations. |
| Molecular Weight | 206.28 |
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg per day without prescription, 2400 mg per day with prescription.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-59 mL/min: reduce dose by 50% or extend interval to every 8 hours; eGFR <30 mL/min: avoid use or maximum 200 mg every 12 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use. |
| Pediatric use | 6 months to 12 years: 5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day or 1200 mg daily (whichever lower). |
| Geriatric use | Start at lowest effective dose (200 mg every 6-8 hours); maximum 1200 mg per day; monitor renal function and gastrointestinal tolerance. |
| 1st trimester | Risk of fetal cardiovascular malformations and gastroschisis; avoid use unless benefit outweighs risk. |
| 2nd trimester | Risk of premature ductus arteriosus closure and oligohydramnios; avoid use unless benefit outweighs risk. |
| 3rd trimester | Contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and fetal renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for SINE-AID IB (SINE-AID IB).
| Placental transfer | Crosses placenta with fetal serum concentrations reaching 50-100% of maternal levels. |
| Breastfeeding | Excreted into breast milk in low concentrations; use caution due to potential adverse effects on infant's cardiovascular and renal systems. |
| Lactation Rating |
■ FDA Black Box Warning
Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
| Serious Effects |
Hypersensitivity to ibuprofen or any component of the formulationHistory of allergic reactions (e.g., urticaria, asthma) to NSAIDsActive peptic ulcer disease or gastrointestinal bleedingAdvanced renal disease (CrCl <30 mL/min)Severe hepatic impairment or active liver diseaseCardiovascular disease (e.g., recent CABG, severe heart failure)Third trimester of pregnancy
| Precautions | Cardiovascular risk (avoid in severe heart failure), gastrointestinal risk (history of peptic ulcer disease or bleeding), renal toxicity (monitor in renal impairment), hypertension, asthma exacerbation, hepatic impairment, pregnancy (avoid in third trimester). |
| Food/Dietary | Avoid alcohol; may increase risk of gastrointestinal bleeding. No significant food interactions, but taking with food reduces gastric irritation. |
Loading safety data…
| L3 - Moderately Safe |
| Teratogenic Risk | First trimester: Ibuprofen exposure associated with increased risk of cardiac septal defects and gastroschisis (OR 1.2-1.8). Third trimester: Avoid due to risk of premature ductus arteriosus constriction, oligohydramnios, and neonatal renal impairment. Overall FDA Category D for third trimester; Category C for first/second trimesters. |
| Fetal Monitoring | Monitor amniotic fluid index (oligohydramnios risk) and fetal ductus arteriosus Doppler if used beyond 48 hours in third trimester. Maternal monitoring: renal function, blood pressure, and signs of gastrointestinal bleeding. |
| Fertility Effects | NSAIDs including ibuprofen may impair female fertility via inhibition of prostaglandin synthesis, potentially delaying or preventing ovulation. Effect is reversible upon discontinuation. |
| Clinical Pearls | For SINE-AID IB (ibuprofen 200 mg), use the lowest effective dose for the shortest duration to minimize gastrointestinal and renal risks. Avoid in patients with active peptic ulcer disease, severe renal impairment, or history of hypersensitivity to NSAIDs. Advise patients to take with food or milk to reduce gastric irritation. |
| Patient Advice | Take with food or milk to prevent stomach upset. · Do not exceed 6 tablets (1200 mg) in 24 hours unless directed by a doctor. · Avoid alcohol while taking this medication to reduce risk of stomach bleeding. · Stop use and consult a doctor if pain worsens or lasts more than 10 days, or if fever lasts more than 3 days. · Do not use with other NSAID-containing products (e.g., aspirin, naproxen). |